Search Results

You are looking at 31 - 40 of 840 items for :

  • Refine by Access: All x
Clear All
Full access

Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy

Patrick A. Brown and Bijal Shah

Hope remains for patients with acute lymphoblastic leukemia (ALL)—hope to extend life and hope to minimize relapse—according to Patrick A. Brown, MD, and Bijal Shah, MD, who discussed the latest treatment options for ALL during their presentations

Full access

CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer

Adith S. Abraham, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, Daniel G. Stover, and Sarah Asad

assessed features associated with rapid relapse TNBC (rrTNBC) and found that higher stage at diagnosis, younger age at diagnosis, lower income, and insurance type were significantly associated with rrTNBC. The goal of the present study was to identify

Full access

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

Featured Updates to the NCCN Guidelines

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Asher A. Chanan-Khan, Steve E. Coutre, Randall S. Davis, Herbert Eradat, Christopher D. Fletcher, Sameh Gaballa, Armin Ghobadi, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Brian Hill, Paul Kaesberg, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Anthony Mato, Claudio Mosse, Stephen Schuster, Tanya Siddiqi, Deborah M. Stephens, Chaitra Ujjani, Nina Wagner-Johnston, Jennifer A. Woyach, J. Christine Ye, Mary A. Dwyer, and Hema Sundar

Insights discuss the updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with previously untreated and relapsed/refractory disease. First

Full access

Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger, and Adam M. Petrich

with relapsed sALCL Review the options for desensitization in patients with relapsed or refractory sALCL and hypersensitivity to brentuximab vedotin Case Report A 32-year-old woman with a medical history of super obesity (body mass index

Full access

Emerging Therapy for the Treatment of Mantle Cell Lymphoma

Saurabh Rajguru and Brad S. Kahl

consensus exists regarding frontline therapy for MCL, although standards are emerging. The management of relapsed MCL is an area of intense study. This review discusses the current landscape and emerging therapies for MCL in both the front-line and relapsed

Full access

HSR23-118: Assessment of Physician Treatment Preferences for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Wei Gao, Katherine Gaburo, Betsy Lahue, Kalatu Davies, Jon Ukropec, and Monika Jun

CAR T, HCPs estimated that 21.6% of patients were refractory to CAR T and 28.0% relapsed post-CAR T. While 44.0% of HCPs were indifferent to treatment formats, they perceived a large patient preference for subcutaneous (58.7%) versus intravenous (12

Full access

Integrating Immune Therapies for the Treatment of Multiple Myeloma

Lekha Mikkilineni and Surbhi Sidana

Despite significant therapeutic advances in the past 2 decades, multiple myeloma (MM) remains incurable. 1 Patients with relapsed or refractory MM (RRMM) that is refractory to a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and anti

Full access

NCCN Trends

% reporting a preference for HDT/ASCR consolidation after CHOP+/-R induction. Figure 1 Preferred induction therapy. In the relapsed setting ( Figure 2 ), bendamustine+/-R was the most commonly preferred salvage therapy for oncologists in the

Full access

NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia

Neil P. Shah

study, the definition was stringent (MR5.0), but further research confirmed that lowering the threshold to a molecular response of 4.5 or 4.0 did not significantly affect rates of molecular relapse ( Figure 1 ). 2 Figure 1. Impact of different molecular

Full access

Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia

Presented by: Eunice S. Wang

-mutant AML (either newly diagnosed or relapsed/refractory) is now standard of care. The phase III RATIFY study performed in younger patients (aged 18–60 years) with newly diagnosed FLT3 -mutant AML found that individuals receiving midostaurin in